ArticleEpileptic disorders : international epilepsy journal with videotape2026
Bayesian age-period-cohort analysis and trend prediction of epilepsy disease burden in China, 1990-2021.
Article in Epileptic disorders : international epilepsy journal with videotape, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study analyzes the trends, age-period-cohort effects, and influencing factors of epilepsy burden in China from 1990 to 2021, and predicts future burden to support prevention strategies.
methodsData were sourced from the Global Burden of Disease Study (GBD) 2021 study. Joinpoint regression analyzed trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs). The BAPC (Bayesian Age-Period-Cohort) model evaluated age, period, and cohort effects, and an ARIMA (Autoregressive Integrated Moving Average) model projected burden to 2036.
resultsIn 2021, epilepsy cases reached 3.086 million (a 41.67% increase since 1990), while DALYs fell to 1.375 million person-years (a 35.60% decrease). Age-standardized incidence and prevalence increased (average annual percent change [AAPC] = 0.78% and 0.42%, respectively), whereas mortality and DALY rates declined (AAPC = -2.65% and -1.79%). After 2019, incidence and prevalence rose sharply, accompanied by a short-term increase in DALY rates indicating a risk of rebound. Age-specific burden shifted from a unimodal (0-25 years) to a bimodal distribution (0-14 and 30-34 years), with the highest burden now among working-age adults. The DALY rate decreased slowest in youths (20-24 years) and fastest in middle-aged groups (45-55 years). Projections indicate continued declines in mortality but stable yet fluctuating incidence through 2036.
conclusionDespite improved mortality and DALY rates, epilepsy incidence and prevalence have increased, and although the overall DALY rate has declined, a recent uptick since 2019 signals the need for continued vigilance and targeted intervention. The shifting burden toward working-age populations underscores the need for differentiated prevention strategies focusing on young adults and the elderly, emphasizing early intervention and long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.